| Authors: |
Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dutta AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Poletti A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Coorens THH; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Toenges R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Loinaz X; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Wallin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dunford A; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Priebe O; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dagan J; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Boehner CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Horowitz E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Barr H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hevenor L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Towle K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Beesam R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Beckwith JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cordas Dos Santos DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Bertamini L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Greipp PT; Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA., Kübler K; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Krantz Family Center for Cancer Research and Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Arndt PF; Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany., Terragna C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Zamagni E; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Boyle EM; Department of Haematology, Cancer Institute, University College London Cancer Institute, London, UK., Yong K; Department of Haematology, Cancer Institute, University College London Cancer Institute, London, UK., Morgan G; Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Walker BA; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Kastritis E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Hess J; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Stewart C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. gadgetz@broadinstitute.org.; Krantz Family Center for Cancer Research and Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. gadgetz@broadinstitute.org.; Department of Pathology, Harvard Medical School, Boston, MA, USA. gadgetz@broadinstitute.org., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. irene_ghobrial@dfci.harvard.edu. |
